NS
Neeti Srivastava
About Neeti Srivastava
Neeti Srivastava has 9 years in corporate governance. Holds Director role. Currently with 1 company, including Aglotus Pharmaceutical Private Limited and Kamla Rail Communications Private Limited. Formerly with 3 companies, such as Omni Power Systems Infrastructure Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Aglotus Pharmaceutical Private Limited
U24299UP2020PTC135954
|
Director | 13 Feb 2023 | 2020 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
|
Omni Power Systems Infrastructure Private Limited
U45309MH2018PTC318569
|
Director | 20 Dec 2018 | 2018 | Active |
|
Kamla Rail Communications Private Limited
U45206MH2016PTC273720
|
Director | 10 Apr 2018 | 2016 | Strike Off |
|
Kamla Rail Automation Private Limited
U52599DL2016PTC303785
|
Director | 01 Aug 2016 | 2016 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Neeti Srivastava
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neeti Srivastava
Neeti Srivastava has 9 years in corporate governance. Holds Director role. Currently with 1 company, including Aglotus Pharmaceutical Private Limited and Kamla Rail Communications Private Limited. Formerly with 3 companies, such as Omni Power Systems Infrastructure Private Limited. Engaged in General Business. Contributes to corporate operations.
Neeti Srivastava is associated with 1 company as Director.
Neeti Srivastava has expertise in General Business.
Neeti Srivastava has 9 years in corporate governance.